Mounjaro vs Ozempic: Mechanism, Evidence, and Cost

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

From the PlexusDx Education Hub, a plain-language comparison built for readers deciding between two headline incretin therapies. Browse the Peptides & GLP-1 Education Hub

This is an independent editorial comparison; PlexusDx holds no commercial relationship with Novo Nordisk or Eli Lilly.

Mounjaro and Ozempic dominate GLP-1 search queries, yet they are not the same kind of molecule. This comparison, current as of April 2026, walks through how each engages the incretin system, where their FDA labels differ, what the trials measured, and the genetic layer that applies no matter which one a clinician chooses.

Two molecules, one receptor family

Mounjaro is a GIP and GLP-1 dual receptor agonist from Eli Lilly, while Ozempic is a selective GLP-1 receptor agonist from Novo Nordisk. Both act on the GLP-1 receptor across the pancreas, hypothalamus, and gut — slowing gastric emptying, flattening post-meal glucose spikes, and strengthening satiety signals. The defining difference is Mounjaro's added agonism at the GIP receptor, a second incretin arm that Ozempic does not engage.

Where the FDA lines are drawn

Mounjaro carries an FDA approval for type 2 diabetes granted in 2022; the same active ingredient is separately approved as Zepbound for chronic weight management. Ozempic was FDA-approved for type 2 diabetes in 2017 and its active ingredient is widely studied for weight management as well. Those label boundaries shape how each can be prescribed and whether insurance is likely to cover a given use.

Reading the trial record without picking a winner

Mounjaro was studied in the SURPASS program, focused on glycemic and weight outcomes in type 2 diabetes, while Ozempic was studied in the SUSTAIN program for glycemic and cardiovascular outcomes. Some direct data exists — SURPASS evaluated tirzepatide head-to-head against semaglutide 1 mg in type 2 diabetes — but populations and endpoints differ enough that a per-trial reading beats any sweeping declaration of superiority.

Tolerability and the shared class warnings

Both compounds carry the GLP-1 class boxed warning tied to thyroid C-cell tumor findings in rodent studies. The most common side effects for each are gastrointestinal — nausea, vomiting, diarrhea, and constipation — usually most intense during dose escalation. Serious events reported across the class include pancreatitis, gallbladder problems, and acute kidney injury in the setting of dehydration.

What each costs before insurance

Mounjaro's U.S. list price sits at approximately $1,069 per month as of April 2026 (Eli Lilly published pricing), while Ozempic's runs approximately $968 to $1,029 per month over the same period (Novo Nordisk published pricing). Actual out-of-pocket cost swings on insurance coverage, manufacturer savings cards, the indication on the prescription, and whether a compounded alternative is available through a licensed pathway.

The genetics that sit above both drugs

No matter which compound is prescribed, the upstream genetic architecture is shared. Variants in GIPR (the GIP receptor gene, relevant to the GIP arm that distinguishes tirzepatide), GLP1R, FTO, and MC4R influence baseline appetite regulation, satiety, and energy expenditure. These are pathway-level markers; they do not predict response to Mounjaro or Ozempic, but they describe the metabolic terrain either drug has to work on. PlexusDx offers tirzepatide through its Weight Management Protocols, including the Tirzepatide Injection protocol. Before starting, the Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights — covering GIPR, FTO, and MC4R — so a decision starts from your biology rather than guesswork.

More from the Hub: generic semaglutide, discount-card pricing, cash-pay cost without insurance, and coupons with insurance.

Editorial note: this article is educational. PlexusDx offers tirzepatide through its Weight Management Protocols and covers here the mechanism, evidence, and genetic context informing any decision to use it. The Precision Peptide Genetic Test shows how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the formats in the Weight Management Protocols, or map your biology first with the Precision Peptide Genetic Test. Browse the Peptides & GLP-1 Education Hub

Frequently Asked Questions

Does the extra GIP action in Mounjaro matter for me?

Mounjaro engages both the GIP and GLP-1 receptors, whereas Ozempic engages only GLP-1. Whether that second arm changes your experience depends on individual biology and cannot be assumed from the mechanism alone. A clinician weighs your history, indication, and goals rather than the receptor count in isolation.

Can I switch between Ozempic and Mounjaro?

Switching between GLP-1 medications is a clinical decision that accounts for indication, tolerability, dose titration, and coverage. Because the molecules differ and dosing does not translate one-to-one, any change should be planned with your prescriber rather than managed independently between the two products.

Does the Precision Peptide Genetic Test tell me which one to take?

No. The test does not predict response to Mounjaro, Ozempic, or any medication. It reads pathway-level variants in GIPR and FTO, and MC4R that describe baseline GLP-1 and energy-balance biology — upstream context that applies whichever compound a clinician ultimately recommends.

Why do the list prices differ?

The two are made by different manufacturers with separate pricing, so Mounjaro and Ozempic carry different list figures as of April 2026. What you actually pay depends far more on coverage, savings cards, the prescribed indication, and compounded-alternative availability than on the headline list price alone.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.